{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:58:16Z","timestamp":1771981096724,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research"},{"DOI":"10.13039\/100015293","name":"Policy-Based Medical Services Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39093-3","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:35:58Z","timestamp":1770388558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatment"],"prefix":"10.1038","volume":"16","author":[{"given":"Shinya","family":"Takada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Uozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Iwabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Kusuhara-Mamishin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanae","family":"Tahatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kitahora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinkichi","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Asano-Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ohnuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Futamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-7908","authenticated-orcid":false,"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"39093_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"Cancer J. Clin."},{"key":"39093_CR2","unstructured":"Cancer Statistics in Japan. Cancer Information Services, Cancer type statistical information Breast. Japan: National Cancer Center. (2025). Available at https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/14_breast.html [in Japanese]. Accessed January 28."},{"key":"39093_CR3","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","volume":"106","author":"N Howlader","year":"2014","unstructured":"Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl. Cancer Inst. 106, dju055. https:\/\/doi.org\/10.1093\/jnci\/dju055 (2014).","journal-title":"J. Natl. Cancer Inst."},{"key":"39093_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N Engl. J. Med."},{"key":"39093_CR5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.23.00137","volume":"42","author":"DJ Slamon","year":"2024","unstructured":"Slamon, D. J. et al. Overall survival with Palbociclib plus letrozole in advanced breast cancer. J. Clin. Oncol. 42, 994\u20131000 (2024).","journal-title":"J. Clin. Oncol."},{"key":"39093_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus Palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425\u2013439 (2016).","journal-title":"Lancet Oncol."},{"key":"39093_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C. et al. Overall survival with Palbociclib and fulvestrant in advanced breast cancer. N Engl. J. Med. 379, 1926\u20131936 (2018).","journal-title":"N Engl. J. Med."},{"key":"39093_CR8","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi, G. N. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl. J. Med. 375, 1738\u20131748 (2016).","journal-title":"N Engl. J. Med."},{"key":"39093_CR9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi, G. N. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann. Oncol. 29, 1541\u20131547 (2018).","journal-title":"Ann. Oncol."},{"key":"39093_CR10","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36, 2465\u20132472 (2018).","journal-title":"J. Clin. Oncol."},{"key":"39093_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon, D. J. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl. J. Med. 382, 514\u2013524 (2020).","journal-title":"N Engl. J. Med."},{"key":"39093_CR12","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge, G. W. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875\u20132884 (2017).","journal-title":"J. Clin. Oncol."},{"key":"39093_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2020","unstructured":"Sledge, G. W. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 6, 116\u2013124 (2020).","journal-title":"JAMA Oncol."},{"key":"39093_CR14","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638\u20133646 (2017).","journal-title":"J. Clin. Oncol."},{"key":"39093_CR15","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz, M. P. et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann. Oncol. 35, 718\u2013727 (2024).","journal-title":"Ann. Oncol."},{"key":"39093_CR16","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston, S. R. D. et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J. Clin. Oncol. 38, 3987\u20133998 (2020).","journal-title":"J. Clin. Oncol."},{"key":"39093_CR17","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1111\/cas.14554","volume":"111","author":"YS Yap","year":"2020","unstructured":"Yap, Y. S. et al. Ribociclib, a CDK 4\/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer. Cancer Sci. 111, 3313\u20133326 (2020).","journal-title":"Cancer Sci."},{"key":"39093_CR18","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cpdd.356","volume":"6","author":"W Sun","year":"2017","unstructured":"Sun, W. et al. Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions. Clin. Pharmacol. Drug Dev. 6, 614\u2013626 (2017).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"39093_CR19","doi-asserted-by":"publisher","first-page":"100231","DOI":"10.1016\/j.esmoop.2021.100231","volume":"6","author":"M Del Re","year":"2021","unstructured":"Del Re, M. et al. Drug-drug interactions between Palbociclib and proton pump inhibitors May significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open. 6, 100231. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100231 (2021).","journal-title":"ESMO Open."},{"key":"39093_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12885-022-09624-y","volume":"22","author":"K Eser","year":"2022","unstructured":"Eser, K. et al. Proton pump inhibitors May reduce the efficacy of ribociclib and Palbociclib in metastatic breast cancer patients based on an observational study. BMC Cancer. 22, 516. https:\/\/doi.org\/10.1186\/s12885-022-09624-y (2022).","journal-title":"BMC Cancer"},{"key":"39093_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.clbc.2023.05.009","volume":"23","author":"T Schieber","year":"2023","unstructured":"Schieber, T. et al. Effect of concurrent proton pump inhibitors with Palbociclib tablets for metastatic breast cancer. Clin. Breast Cancer. 23, 658\u2013663 (2023).","journal-title":"Clin. Breast Cancer"},{"key":"39093_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2022.10.005","volume":"66","author":"M Del Re","year":"2022","unstructured":"Del Re, M. et al. Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. Breast 66, 157\u2013161 (2022).","journal-title":"Breast"},{"key":"39093_CR23","doi-asserted-by":"publisher","first-page":"e741","DOI":"10.1093\/oncolo\/oyae015","volume":"29","author":"K Takahashi","year":"2024","unstructured":"Takahashi, K. et al. Proton pump inhibitors and cyclin-dependent kinase 4\/6 inhibitors in patients with breast cancer. Oncologist 29, e741\u2013e749 (2024).","journal-title":"Oncologist"},{"key":"39093_CR24","doi-asserted-by":"publisher","first-page":"e2324852","DOI":"10.1001\/jamanetworkopen.2023.24852","volume":"6","author":"JE Lee","year":"2023","unstructured":"Lee, J. E. et al. Concomitant use of proton pump inhibitors and Palbociclib among patients with breast cancer. JAMA Netw. Open. 6, e2324852. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.24852 (2023).","journal-title":"JAMA Netw. Open."},{"key":"39093_CR25","doi-asserted-by":"publisher","first-page":"103761","DOI":"10.1016\/j.breast.2024.103761","volume":"76","author":"S Di Cosimo","year":"2024","unstructured":"Di Cosimo, S. et al. Impact of coadministration of proton-pump inhibitors and Palbociclib in hormone receptor-positive\/HER2-negative advanced breast cancer. Breast 76, 103761. https:\/\/doi.org\/10.1016\/j.breast.2024.103761 (2024).","journal-title":"Breast"},{"key":"39093_CR26","doi-asserted-by":"publisher","first-page":"104096","DOI":"10.1016\/j.esmoop.2024.104096","volume":"10","author":"E Agostinetto","year":"2025","unstructured":"Agostinetto, E. et al. Drug-drug interactions between Palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42\/AFT-05\/BIG-14-13\/PrE0109). ESMO Open. 10, 104096. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104096 (2025).","journal-title":"ESMO Open."},{"key":"39093_CR27","doi-asserted-by":"publisher","first-page":"117822342098384","DOI":"10.1177\/1178223420983843","volume":"14","author":"N Odan","year":"2020","unstructured":"Odan, N. et al. Real-world outcomes of treating advanced breast cancer patients with palbociclib: a multicenter retrospective cohort study in Japan-the KBCOG-14 study. Breast Cancer (Auckl). 14, 1178223420983843. https:\/\/doi.org\/10.1177\/1178223420983843 (2020).","journal-title":"Breast Cancer (Auckl)"},{"key":"39093_CR28","doi-asserted-by":"publisher","first-page":"7665","DOI":"10.1002\/cam4.4295","volume":"10","author":"J Sun","year":"2021","unstructured":"Sun, J. et al. Real-world benefit of combination Palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. Cancer Med. 10, 7665\u20137672 (2021).","journal-title":"Cancer Med."},{"key":"39093_CR29","doi-asserted-by":"publisher","unstructured":"Kim, C. G. et al. On-treatment derived neutrophil-to-lymphocyte ratio and survival with Palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2\/3 study with immune correlates. Breast Cancer Res. 25 https:\/\/doi.org\/10.1186\/s13058-022-01601-4 (2023).","DOI":"10.1186\/s13058-022-01601-4"},{"key":"39093_CR30","doi-asserted-by":"publisher","first-page":"1105587","DOI":"10.3389\/fonc.2022.1105587","volume":"12","author":"P Rottier","year":"2022","unstructured":"Rottier, P. et al. Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with Cyclin dependent kinase 4\/6 inhibitors. Front. Oncol. 12, 1105587. https:\/\/doi.org\/10.3389\/fonc.2022.1105587 (2022).","journal-title":"Front. Oncol."},{"key":"39093_CR31","doi-asserted-by":"publisher","unstructured":"Nakamoto, S. et al. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4\/6 inhibitor efficacy in advanced breast cancer. Sci. Rep. 14 https:\/\/doi.org\/10.1038\/s41598-024-60101-x (2024).","DOI":"10.1038\/s41598-024-60101-x"},{"key":"39093_CR32","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453\u20131457 (2007).","journal-title":"Lancet"},{"key":"39093_CR33","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","volume":"34","author":"HS Rugo","year":"2016","unstructured":"Rugo, H. S. et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J. Clin. Oncol. 34, 3069\u20133103 (2016).","journal-title":"J. Clin. Oncol."},{"key":"39093_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"39093_CR35","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). version 5.0. (2025). Available at https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed January 30."},{"key":"39093_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/sim.4780050306","volume":"5","author":"EL Korn","year":"1986","unstructured":"Korn, E. L. Censoring distributions as a measure of follow-up in survival analysis. Stat. Med. 5, 255\u2013260 (1986).","journal-title":"Stat. Med."},{"key":"39093_CR37","doi-asserted-by":"publisher","first-page":"102956","DOI":"10.1016\/j.ctrv.2025.102956","volume":"137","author":"TK Sahin","year":"2025","unstructured":"Sahin, T. K. et al. Drug-drug interactions and special considerations in breast cancer patients treated with CDK4\/6 inhibitors: A comprehensive review. Cancer Treat. Rev. 137, 102956 (2025).","journal-title":"Cancer Treat. Rev."},{"key":"39093_CR38","unstructured":"Cabinet Office, Government of Japan. Public Opinion Survey on the Use of Pharmacies. (2020). Available at: https:\/\/survey.gov-online.go.jp\/r02\/r02-yakkyoku\/. Accessed January 11, 2026."},{"key":"39093_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1081\/DMR-120023681","volume":"35","author":"T Mizutani","year":"2003","unstructured":"Mizutani, T. PM frequencies of major cyps in Asians and Caucasians. Drug Metab. Rev. 35, 99\u2013106 (2003).","journal-title":"Drug Metab. Rev."},{"key":"39093_CR40","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein, H. J. et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J. Clin. Oncol. 39, 3959\u20133977 (2021).","journal-title":"J. Clin. Oncol."},{"key":"39093_CR41","unstructured":"Gradishar, W. J. et al. NCCN Clinical Practice Guidelines in Oncology Breast Cancer. version 1; (2025). Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed February 02, 2025."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39093-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:05:14Z","timestamp":1771977914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39093-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39093"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39093-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.U. received consulting\/advisory relationships from Eisai, Sawai Pharmaceutical, SBI Pharmaceuticals, Daiichi Sankyo, Statcom, and EPS Corporation and honoraria from Janssen Pharmaceutical, SAS Institute Japan, and Nippon Kayaku outside the submitted work. T.M. received grants from Sysmex, Eisai, MSD, Pfizer, Novartis, Chugai, AstraZeneca, Ono, Daiichi Sankyo, and Gilead Sciences and lecture fees from Eisai, Pfizer, Novartis, Chugai, Eli Lilly, AstraZeneca, Kyowa Kirin, Taiho, and Daiichi Sankyo outside the submitted work. T.H. received a research grant from Eli Lilly and lecture fees from Eli Lilly and Pfizer outside the submitted work. H.I. received consulting fees from Astellas, Daiichi Sankyo, and Taiho, consulting fees provided to the institution from Eisai and Taiho, and lecture fees from Astellas, AstraZeneca, Chugai, Daiichi Sankyo, Eli Lilly, Nippon Kayaku, Ohara, Sawai, Taiho, and Yakult outside of the submitted work. K.K.M. received payments for presentations from Daiichi Sankyo and Merck Serono, and payment for expert testimony from Daiichi Sankyo outside the submitted work. Y.K. received grants provided to the institution by Asahi Kasei, Ono, Otsuka, Nippon Covidien, Taiho, Chugai, Kaken, EA Pharma, Yakult, Otsuka, Tsumura, Sumitomo, Eisai, Kyowa Kirin, Takeda, Teijin, Cardinal Health, and Kowa, and personal fees from Asahi Kasei, AstraZeneca, Ethicon, Ono, Otsuka, Olympus, Cardinal Health, Shionogi, Taiho, Chugai, Bristol-Myers Squibb, MSD, Smith & Nephew, Kaken, Aska, Miyarisan, Toray Industries, Daiichi Sankyo, Chugai Foundation for Innovative Drug Discovery Science, Nippon Kayaku, EA Pharma, Intuitive Surgical, Takeda, Sysmex, Tsumura, and Joint Research Laboratory for Development and Education of Innovative Medical Technology of Sysmex and Medicaroid Corporation outside the submitted work. M.K. received a lecture fee from Eisai outside of the submitted work. A.N. received lecture fees from Chugai, Pfizer, and Daiichi Sankyo and owned Chugai stock. M.F. received lecture fees from Daiichi Sankyo, Taiho Chugai, Eisai, Eli Lilly, and Nippon Kayaku outside the submitted work. The authors have no competing financial interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7551"}}